Literature DB >> 8880547

Financial burden of hospital-acquired Clostridium difficile infection.

M H Wilcox1, J G Cunniffe, C Trundle, C Redpath.   

Abstract

Clostridium difficile infection has become endemic in many hospitals and yet few data on the associated costs of such cases are available. We prospectively followed 50 consecutive cases of C. difficile infection and 92 control patients, who were admitted to the same geriatric wards within 72 h of the cases. Cases and controls had similar age, sex and major diagnosis distributions. Cases stayed significantly longer (mean 21.3 days, median 20.5 days; P < 0.001) in hospital than controls, including an average 14 days in a side room. Diarrhoea developed in cases on average 10.8 days after admission, which, when compared with a mean duration of stay for controls of 25.2 days, implies that C. difficile infection caused an increased duration of stay, as opposed to infection occurring because of longer residence. There was a significantly higher death rate in cases compared with controls (P < 0.01). Antibiotic treatment of C. difficile infection cost an average of Pounds 47 per case. The average number of laboratory investigations per day was similar for cases and controls, but the increased length of stay meant an extra cost for tests of approximately Pounds 210 per case. Assuming hotel costs of Pounds 150 (Pounds 200) per day stay (in a side room), 94% of the additional costs associated with C. difficile infection were due to increased duration of stay (Pounds 3850). The total identifiable increased cost of C. difficile infection was, therefore, in excess of Pounds 4000 per case. Such high costs can be used to justify expenditure on personnel and/or other control measures to reduce the incidence of this hospital-acquired infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8880547     DOI: 10.1016/s0195-6701(96)90122-x

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  45 in total

1.  Choosing the right antibiotic. Right drug at right time in right dose saves lives.

Authors:  D Bihari
Journal:  BMJ       Date:  1999-10-02

Review 2.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

3.  The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital.

Authors:  Alan J Forster; Monica Taljaard; Natalie Oake; Kumanan Wilson; Virginia Roth; Carl van Walraven
Journal:  CMAJ       Date:  2011-12-05       Impact factor: 8.262

4.  Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection.

Authors:  Sahil Khanna; Arjun Gupta; Larry M Baddour; Darrell S Pardi
Journal:  Intern Emerg Med       Date:  2015-12-22       Impact factor: 3.397

5.  Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec.

Authors:  Jacques Pépin; Louis Valiquette; Benoit Cossette
Journal:  CMAJ       Date:  2005-09-22       Impact factor: 8.262

6.  Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.

Authors:  Y K Shue; P S Sears; S Shangle; R B Walsh; C Lee; S L Gorbach; F Okumu; R A Preston
Journal:  Antimicrob Agents Chemother       Date:  2008-02-11       Impact factor: 5.191

7.  Clostridium difficile: a pathogen of the nineties.

Authors:  T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

Review 8.  Costs of hospital-acquired infection and transferability of the estimates: a systematic review.

Authors:  H Fukuda; J Lee; Y Imanaka
Journal:  Infection       Date:  2011-03-22       Impact factor: 3.553

9.  Translocation of Clostridium difficile toxin B across polarized Caco-2 cell monolayers is enhanced by toxin A.

Authors:  Tim Du; Michelle J Alfa
Journal:  Can J Infect Dis       Date:  2004-03

10.  N-CDAD in Canada: results of the Canadian Nosocomial Infection Surveillance Program 1997 N-CDAD Prevalence Surveillance Project.

Authors:  M Hyland; M Ofner-Agostini; M Miller; S Paton; M Gourdeau; M Ishak
Journal:  Can J Infect Dis       Date:  2001-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.